Lorlatinib Induces Rapid and Durable Response in Refractory Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma

JCO Precis Oncol. 2023 Feb:7:e2200536. doi: 10.1200/PO.22.00536.
No abstract available

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Humans
  • Lactams*
  • Lactams, Macrocyclic / pharmacology
  • Lymphoma, B-Cell*

Substances

  • lorlatinib
  • Anaplastic Lymphoma Kinase
  • Lactams, Macrocyclic
  • Lactams